SGMT Sagimet Biosciences Inc.

Fundamentals / CIK 0001400118 / USD

Sagimet Biosciences Inc. reported $282.1M in total assets and a net loss of $53.32M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open SGMT in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$7.36M$3.68M$0-$47.89MFY 2022 Net Income: -$30.50M2022FY 2023 Revenue: $2.00MFY 2023 Net Income: -$27.88M2023FY 2024 Net Income: -$45.57M2024FY 2025 Net Income: -$51.04M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31
Revenue -- -- $2.00M --
Research & Development $39.05M $38.44M $19.78M $24.92M
Total Operating Expenses $56.89M $54.45M $32.74M $31.05M
Operating Income -$56.89M -$54.45M -$30.74M -$31.05M
Income Tax Expense $0 $0 -- --
Net Income -$51.04M -$45.57M -$27.88M -$30.50M
Basic EPS -$1.58 -$1.45 -$2.66 -$165.20
Diluted EPS -$1.58 -$1.45 -$2.66 -$165.20
Basic Shares Outstanding 32.3M 31.4M 10.5M 184.6K
Diluted Shares Outstanding 32.3M 31.4M 10.5M 184.6K

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Research & Development $16.34M $11.54M $7.00M $6.73M $9.73M $7.25M $15.34M $14.22M
Total Operating Expenses $21.57M $15.82M $11.71M $10.77M $14.33M $11.93M $19.86M $18.20M
Operating Income -$21.57M -$15.82M -$11.71M -$10.77M -$14.33M -$11.93M -$19.86M -$18.20M
Net Income -$19.15M -$13.95M -$10.65M -$9.57M -$12.91M -$10.39M -$18.18M -$16.20M
Basic EPS -$0.31 -$0.26 -$0.33 -- -$0.40 -$0.32 -$0.56 --
Diluted EPS -$0.31 -$0.26 -$0.33 -- -$0.40 -$0.32 -$0.56 --
Basic Shares Outstanding 62.3M 53.1M 32.6M -- 32.5M 32.2M 32.2M --
Diluted Shares Outstanding 62.3M 53.1M 32.6M -- 32.5M 32.2M 32.2M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $35.02M $75.84M $75.14M $158K
Short-Term Investments $78.10M $75.41M $19.76M $32.19M
Cash & Short-Term Investments $113.1M $158.7M $94.90M $32.34M
Other Current Assets $199K $157K $74K $34K
Total Current Assets $116.4M $152.8M $96.65M $32.79M
Long-Term Investments $0 $7.41M -- --
Other Non-Current Assets $0 -- -- --
Total Non-Current Assets $78K $7.49M $73K $239K
Total Assets $116.5M $160.3M $96.72M $33.03M
Accounts Payable $1.31M $1.43M $186K $1.12M
Other Current Liabilities $27K $5.0K $233K $57K
Total Current Liabilities $5.10M $4.45M $5.65M $5.28M
Total Non-Current Liabilities $0 $0 $0 $82K
Total Liabilities $5.10M $4.45M $5.65M $5.36M
Total Debt (incl. Leases) $78K $78K $65K $211K
Common Stock -- -- -- $1.0K
Retained Earnings -$346.3M -$295.3M -$249.7M -$221.9M
Accumulated Other Comp. Income $120K $230K $30K -$84K
Total Stockholders' Equity $111.4M $155.8M $91.06M -$186.9M
Total Equity $111.4M $155.8M $91.06M -$186.9M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Cash & Cash Equivalents $111.0M $165.9M $36.63M $35.02M $32.50M $42.33M $64.72M $75.84M
Short-Term Investments $125.4M $74.23M $67.91M $78.10M $84.20M $83.08M $79.85M $75.41M
Cash & Short-Term Investments $275.8M $257.6M $104.5M $113.1M $125.5M $135.5M $144.6M $158.7M
Other Current Assets $302K $226K $248K $199K $253K $173K $263K $157K
Total Current Assets $240.7M $244.0M $107.7M $116.4M $119.5M $127.2M $146.1M $152.8M
Long-Term Investments $39.42M $17.44M -- $0 $8.81M $10.06M -- $7.41M
Other Non-Current Assets $55K $55K -- $0 -- -- $62K --
Total Non-Current Assets $41.37M $19.44M $39K $78K $8.92M $10.21M $100K $7.49M
Total Assets $282.1M $263.4M $107.8M $116.5M $128.4M $137.4M $146.2M $160.3M
Accounts Payable $1.81M $1.13M $2.30M $1.31M $4.24M $1.92M $3.22M $1.43M
Other Current Liabilities $13K $26K $15K $27K $8.0K $1.0K $16K $5.0K
Total Current Liabilities $37.98M $5.42M $5.30M $5.10M $9.15M $7.25M -- $4.45M
Total Non-Current Liabilities $1.93M $1.86M $0 $0 $0 $0 -- $0
Total Liabilities $39.91M $7.28M $5.30M $5.10M $9.15M $7.25M $7.18M $4.45M
Total Debt (incl. Leases) $2.02M $1.94M $39K $78K $115K $152K $39K $78K
Retained Earnings -$390.1M -$371.0M -$357.0M -$346.3M -$336.8M -$323.9M -$313.5M -$295.3M
Accumulated Other Comp. Income -$560K -$77K $8.0K $120K $117K $76K $121K $230K
Total Stockholders' Equity $242.2M $256.2M $102.5M $111.4M $119.3M $130.2M $139.0M $155.8M
Total Equity $242.2M $256.2M $102.5M $111.4M $119.3M $130.2M $139.0M $155.8M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31
Net Income -$51.04M -$45.57M -$27.88M -$30.50M
Stock-Based Compensation $6.45M $5.29M $4.99M $1.88M
Operating Cash Flow -$45.65M -$42.44M -$23.77M -$24.49M
Purchases of Investments -$106.9M -$108.1M -$19.62M -$41.45M
Investing Cash Flow $4.56M -$61.68M $12.58M -$32.01M
Common Stock Issued $0 $105.8M -- --
Financing Cash Flow $275K $104.8M $86.17M -$73K
Net Change in Cash $1.60M -$11.12M $1.88M $101.7M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Net Income -$19.15M -$13.95M -$10.65M -$9.57M -$12.91M -$10.39M -$18.18M -$16.20M
Stock-Based Compensation $2.39M $3.69M $1.84M $1.69M $1.69M $1.60M $1.47M $1.53M
Operating Cash Flow -$12.11M -$11.10M -$8.61M -$11.83M -$10.18M -$9.10M -$14.54M -$11.02M
Purchases of Investments -$98.72M -$39.90M -$6.75M -$17.08M -$31.26M -$42.95M -$15.57M --
Investing Cash Flow -$73.25M -$24.02M $10.22M $14.36M $75K -$13.29M $3.41M $9.85M
Common Stock Issued -- -- -- -- -- -- -- $0
Financing Cash Flow -- -- -- -- -- -- -- $0

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31
Operating Margin -- -- -1537.0% --
Net Profit Margin -- -- -1393.8% --
Return on Equity (ROE) -45.8% -29.2% -30.6% --
Return on Assets (ROA) -43.8% -28.4% -28.8% -92.3%
Current Ratio 22.82x 34.30x 17.09x 6.21x
Quick Ratio 22.17x 35.63x 16.78x 6.13x
Debt to Equity 0.00x 0.00x 0.00x --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Return on Equity (ROE) -22.0% -18.4% -42.5% -45.8% -48.4% -45.6% -41.1% -29.2%
Return on Assets (ROA) -18.9% -17.9% -40.4% -43.8% -44.9% -43.2% -39.1% -28.4%
Current Ratio 6.34x 45.02x 20.34x 22.82x 13.06x 17.55x -- 34.30x
Quick Ratio 7.26x 47.54x 19.73x 22.17x 13.72x 18.70x -- 35.63x
Debt to Equity 0.01x 0.01x 0.00x 0.00x 0.00x 0.00x 0.00x 0.00x
Source: SEC EDGAR CompanyFacts (CIK 0001400118) · from March 31, 2022 Data through September 30, 2026 · synced Nov 20, 2026, 05:39 UTC · Open in terminal